Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France

[1]  J. Snoeys,et al.  In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity , 2016, Drug Metabolism and Disposition.

[2]  S. Berry,et al.  High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate , 2016, European Journal of Clinical Pharmacology.

[3]  D. Somford,et al.  Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide , 2016, Clinical Pharmacokinetics.

[4]  C. Kollmannsberger,et al.  Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer , 2015, Journal of clinical pharmacology.

[5]  Justin Fongemie,et al.  A Review of Nebivolol Pharmacology and Clinical Evidence , 2015, Drugs.

[6]  P. Neuvonen,et al.  Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol , 2015, European Journal of Clinical Pharmacology.

[7]  T. Beer,et al.  Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents , 2014, Drugs & Aging.

[8]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[9]  Siran Koroukian,et al.  Patient Characteristics Associated with Polypharmacy and Inappropriate Prescribing of Medications among Older Adults with Cancer. , 2012, Journal of geriatric oncology.

[10]  G. Petersson,et al.  Factors leading to excessive polypharmacy. , 2012, Clinics in geriatric medicine.

[11]  Y. Daali,et al.  Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview. , 2012, Basic & clinical pharmacology & toxicology.

[12]  J. Lees,et al.  Polypharmacy in elderly patients with cancer: clinical implications and management. , 2011, The Lancet. Oncology.

[13]  S. Goutelle,et al.  Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions , 2011, Clinical pharmacokinetics.

[14]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[15]  M. Extermann,et al.  Comprehensive geriatric assessment for older patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Bernard,et al.  Impact on abiraterone pharmacokinetics and safety: Open‐label drug–drug interaction studies with ketoconazole and rifampicin , 2015, Clinical pharmacology in drug development.

[17]  F. Goldwasser,et al.  Drug interactions with solid tumour-targeted therapies. , 2014, Critical reviews in oncology/hematology.

[18]  A. Tolcher,et al.  Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer , 2012, Cancer Chemotherapy and Pharmacology.

[19]  K. Yap,et al.  Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. , 2009, Clinical therapeutics.